03 October 2024
03 October 2024
With fully functional inpatient and recovery units, as well as operating rooms, the Centre is now prepared to significantly expand the Champalimaud Foundation's capacity to treat pancreatic cancer patients. With a dedicated team of specialists in the treatment and research of this type of cancer, the Centre's mission is to deliver the highest standard of clinical care.
02 October 2024
Natural ageing is one of the main risk factors for cancer. As we become older, the probability of developing cancer increases. This happens, on the one hand, because the probability of acquiring cancer-causing mutations grows as we live longer; and on the other, because our DNA repair mechanisms decline with age.
05 September 2024
The ERC Starting Grant is one of Europe’s most prestigious and competitive research awards, designed to support promising early-career researchers who have the potential to become leaders in their fields. Ianuş will receive €2M over the next five years to develop her research project at King’s College London, where she recently joined as a Lecturer in Healthcare Engineering.
08 August 2024
Using zebrafish “Avatars”, an animal model developed by the Cancer Development and Innate Immune Evasion lab at the Champalimaud Foundation (CF), led by Rita Fior, Mayra Martínez-López – a former PhD student at the lab now working at the Universidad de las Américas in Quito, Ecuador – and colleagues studied the initial steps of the Bacillus Calmette-Guérin (BCG) vaccine’s action on bladder cancer cells.
18 July 2024
Experts from two international nuclear medicine societies (EANM and SNMMI) have joined those from important societies of various other medical specialities involved in the care of breast cancer patients – including oncology, surgery, radio-oncology and breast imaging – to draw up a set of recommendations, based on scientific evidence, on the correct utilisation, in breast cancer, of a medical imaging exam. The exam in question has been used for several years and involves radioactive substances, in this case a glucose analogue called fluorodeoxyglucose (FDG).
11 Jul. 2024
THIS CALL IS NOW CLOSED
Champalimaud Foundation (Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud), a private, non-profit research institution in Lisbon, Portugal, is looking for a 2 Postdocs to join our team at the Champalimaud Research Program.
The position